Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2022-06-09 00:00:00 ET · period of report 2022-06-08 · accession 0001867096-22-000092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-09 | 2022-06-08 | XERS | HALKUFF DAWN | Dir | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
| D | 2022-06-09 | 2022-06-08 | XERS | HALKUFF DAWN | Dir | A - Grant | $0.00 | +25.0K | 25.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-08 | A | A | 15,000 | $0.00 | 15,000 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-06-08 | A | A | 25,000 | $0.00 | 25,000 | D | $2.10 · 2022-06-08 to 2032-06-08 | 25,000 Common Stock | (F2) Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders. |